Hypertensive patients from two rural Chinese counties respond differently to benazepril: The anhui hypertension health care study

Annals of Epidemiology

Volumn 14, Issue 2, 2004, Pages 123-128

  Li, Dong ^a   Xing, Houxun ^b   Hao, Ke ^b,e   Peng, Shaojie ^b   Wu, Di ^b   Guang, Wenwei ^b   Huang, Aiqun ^b   Wang, Yuanping ^b   Zhang, Yan ^c,d   Yu, Yunxian ^a   Li, Jianping ^b   Chen, Changzhong ^b   Wang, Binyan ^b   Zhu, Guoying ^c   Huo, Yong ^c   Chen, Dafang ^b,c   Ronnenberg, Alayne ^e   Niu, Tianhua ^e   Xu, Xiping ^a,b,e  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Benazepril; Hypertension; Pharmacoepidemiology; Response

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHINA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HEREDITY; HUMAN; MALE; PRIORITY JOURNAL; RURAL POPULATION; TREATMENT OUTCOME;

EID: 10744221954     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(03)00118-2     Document Type: Article

References (16)

1. Tao S., Zhou B. Epidemiology of hypertension in China. Clinic Medical Journal (English). 112:(10):1999;878-882.
2. Luft F.C. Hypertension as a complex genetic trait. Semin Nephrol. 22:(2):2002;115-126.
3. Dosh S.A. The treatment of adults with essential hypertension. J Fam Pract. 51:(1):2002;74-80.
4. Lobo M. Current thinking in the treatment of hypertension. Practitioner. 246:(1635):2002;408-410. 413-414.
5. Lloyd-Jones D.M., Evans J.C., Larson M.G., O'Donnell C.J., Roccella E.J., Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 36:(4):2000;594-599.
6. SoRelle R. New rules for high blood pressure. Circulation. 97:(4):1998;307-308.
7. Massie B.M. Demographic considerations in the selection of antihypertensive therapy. Am J Cardiol. 60:(17):1987;121I-126I.
8. Housman D., Ledley F.D. Why pharmacogenomics? Why now? Nat Biotechnol. 16:(6):1998;492-493.
9. Balfour J.A., Goa K.L., Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs. 42:(3):1991;511-539.
10. Gengo F.M., Brady E. The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol. 14:(8 suppl. 4):1991;IV44-IV50. discussion IV51-55.
11. MacNab M., Mallows S. Safety profile of benazepril in essential hypertension. Clin Cardiol. 14:(8 suppl. 4):1991;IV33-IV37. discussion IV51-55.
12. Postma C.T., Dennesen P.J., de Boo T., Thien T. First dose hypotension after captopril; can it be predicted? A study of 240 patients. J Hum Hypertens. 6:(3):1992;205-209.
13. Palatini P., Mos L., Motolese M., Mormino P., Del Torre M., Varotto L., et al. Effect of evening versus morning benazepril on 24-hour blood pressure: a comparative study with continuous intra-arterial monitoring. Int J Clin Pharmacol Ther Toxicol. 31:(6):1993;295-300.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:(6):1972;499-502.
15. Suter P.M., Sierro C., Vetter W. Nutritional factors in the control of blood pressure and hypertension. Nutr Clin Care. 5:(1):2002;9-19.
16. Hooper L., Bartlett C., Davey Smith G., Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 325:(7365):2002;628-632.